The majority of clinical degraders utilize an immunomodulatory imide drug (IMiD)-based derivative, that directs their target to the E3 ligase receptor Cereblon (CRBN), however, identification of new IMiD molecular glue substrates has remained underexplored. To tackle this, we design human CRBN const...
ORGANISM(S): Homo sapiens (Human)
